A new analysis of the landmark Systolic Blood Pressure Intervention Trial (SPRINT) reveals that intensive blood pressure control (target <120 mmHg) provides net clinical benefits for nearly all adults with chronic kidney disease (CKD) compared to standard treatment (<140 mmHg).
The study, to be presented at ASN Kidney Week 2025 (November 5-9), demonstrates that aggressive BP management’s benefits—reduced mortality, cardiovascular events, and cognitive impairment—significantly outweigh treatment-related harms across CKD stages. These findings provide robust evidence supporting current KDIGO guidelines recommending tighter BP control for hypertensive CKD patients.
Study Design and Analytical Approach
Researchers conducted a sophisticated benefit-harm tradeoff analysis of 2,012 SPRINT participants with CKD, employing advanced statistical methods to:
Individualized prediction: Model treatment effects for multiple clinical outcomes
Preference weighting: Incorporate patient values regarding different health outcomes
Comprehensive assessment: Evaluate both benefits (mortality reduction, cardiovascular event prevention) and harms (ER visits, hospitalizations for AKI, syncope)
The analysis represents one of the most comprehensive evaluations of intensive BP management’s risk-benefit profile in CKD patients to date.
Key Findings and Clinical Implications
The results demonstrated overwhelming net benefit for intensive BP control:
Universal benefit: 100% of participants showed positive net benefit when accounting for patient preferences
Robust findings: 90% maintained positive net benefit even when assuming equal importance for benefits and harms
Disease stage impact: Advanced CKD patients (eGFR 20-44 mL/min/1.73m²) experienced greater absolute benefits despite higher absolute risks
Guideline alignment: Supports KDIGO recommendation of <120 mmHg target for hypertensive CKD adults
Clinical Applications and Implementation
“These findings should help overcome therapeutic inertia commonly encountered when intensifying BP control in CKD patients,” noted the research team. The analysis provides clinicians with strong evidence to:
- Confidently pursue lower BP targets in appropriate patients
- Address patient and provider concerns about treatment-associated risks
- Support shared decision-making with quantitative benefit-harm assessments
- Implement guideline-recommended BP targets more consistently
Patient-Centered Care and Future Directions
The study’s novel methodology—incorporating patient preferences into benefit-harm calculations—represents a significant advancement in personalized medicine for CKD management. Future research should focus on:
- Validating these findings in real-world clinical settings
- Developing practical tools for individualized benefit-harm assessment
- Identifying patient subgroups that might require different treatment approaches
- Exploring implementation strategies to overcome therapeutic inertia
Related topics
